BRPI0414724A - combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit - Google Patents

combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit

Info

Publication number
BRPI0414724A
BRPI0414724A BRPI0414724-3A BRPI0414724A BRPI0414724A BR PI0414724 A BRPI0414724 A BR PI0414724A BR PI0414724 A BRPI0414724 A BR PI0414724A BR PI0414724 A BRPI0414724 A BR PI0414724A
Authority
BR
Brazil
Prior art keywords
warm
blooded animal
preventing
combination
methods
Prior art date
Application number
BRPI0414724-3A
Other languages
English (en)
Inventor
Jay Lal Mehta
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of BRPI0414724A publication Critical patent/BRPI0414724A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Abstract

"COMBINAçãO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA PREVENIR OU TRATAR ATEROSCLEROSE EM UM ANIMAL DE SANGUE QUENTE E PARA PREVENIR EVENTOS CARDIOVASCULARES EM UM ANIMAL DE SANGUE QUENTE, E, KIT". é descrita uma combinação compreendendo candesartano e rosuvastatina, para a prevenção ou tratamento da arteriosclerose e para a prevenção de eventos cardiovasculares.
BRPI0414724-3A 2003-09-26 2004-09-22 combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit BRPI0414724A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
PCT/GB2004/004120 WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Publications (1)

Publication Number Publication Date
BRPI0414724A true BRPI0414724A (pt) 2006-11-21

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414724-3A BRPI0414724A (pt) 2003-09-26 2004-09-22 combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit

Country Status (28)

Country Link
US (2) US7932263B2 (pt)
EP (1) EP1673091B1 (pt)
JP (1) JP4841433B2 (pt)
KR (1) KR101129767B1 (pt)
CN (1) CN100515421C (pt)
AT (1) ATE451103T1 (pt)
AU (1) AU2004275567B2 (pt)
BR (1) BRPI0414724A (pt)
CA (1) CA2540102C (pt)
CY (1) CY1109814T1 (pt)
DE (1) DE602004024555D1 (pt)
DK (1) DK1673091T3 (pt)
ES (1) ES2336450T3 (pt)
GB (1) GB0322552D0 (pt)
HR (1) HRP20100080T1 (pt)
IL (1) IL174536A (pt)
IS (1) IS2729B (pt)
MX (1) MXPA06003353A (pt)
NO (1) NO335813B1 (pt)
NZ (1) NZ546162A (pt)
PL (1) PL1673091T3 (pt)
PT (1) PT1673091E (pt)
RU (1) RU2358737C2 (pt)
SG (1) SG145773A1 (pt)
SI (1) SI1673091T1 (pt)
UA (1) UA90249C2 (pt)
WO (1) WO2005030215A2 (pt)
ZA (1) ZA200602433B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
BR112012006939A2 (pt) * 2009-09-29 2015-09-08 Butamax Tm Advanced Biofuels célula hospedeira de produção de levedura recombinante e método para a produção de um produto selecionado do grupo que consiste em 2,3-butanodiol, isobutanol, 2-butanol, 1-butanol, 2-butanona, valina, leucina, ácido lático, ácido málico, álcool, isoampilico e isoprenoides
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
HRP20170263T2 (hr) * 2011-12-09 2018-12-28 Ims Medical D.O.O. LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
WO2018093144A1 (ko) * 2016-11-15 2018-05-24 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3883205B2 (ja) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6107323A (en) 1996-04-05 2000-08-22 Takeda Chemical Industries, Ltd. Pharmaceutical composition
AU714618B2 (en) * 1996-07-15 2000-01-06 Sankyo Company Limited Medicinal composition
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
TR200000562T2 (tr) 1997-08-29 2000-08-21 Pfizer Products Inc. Amlodifin ve bir statin bileşiği içeren bileşim terapisi
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HUP0203338A2 (hu) 1999-04-13 2003-03-28 Abbott Gmbh & Co. Kg Integrin receptor ligandumok
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001015744A1 (en) 1999-08-31 2001-03-08 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CA2405793A1 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001284413A1 (en) 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
IL156585A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US20030053950A1 (en) * 2001-04-18 2003-03-20 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
EA008596B1 (ru) * 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
SG145773A1 (en) 2008-09-29
AU2004275567B2 (en) 2008-01-10
US20110046119A1 (en) 2011-02-24
NO20061744L (no) 2006-06-22
NZ546162A (en) 2008-11-28
ATE451103T1 (de) 2009-12-15
CY1109814T1 (el) 2014-09-10
UA90249C2 (uk) 2010-04-26
SI1673091T1 (sl) 2010-03-31
HRP20100080T1 (hr) 2010-04-30
KR20060108623A (ko) 2006-10-18
PT1673091E (pt) 2010-02-15
HK1090553A1 (en) 2006-12-29
ES2336450T3 (es) 2010-04-13
IL174536A (en) 2010-12-30
NO335813B1 (no) 2015-02-23
JP4841433B2 (ja) 2011-12-21
CN100515421C (zh) 2009-07-22
DE602004024555D1 (de) 2010-01-21
EP1673091A2 (en) 2006-06-28
WO2005030215A3 (en) 2005-06-02
PL1673091T3 (pl) 2010-04-30
DK1673091T3 (da) 2010-03-22
EP1673091B1 (en) 2009-12-09
WO2005030215A2 (en) 2005-04-07
ZA200602433B (en) 2007-06-27
CN1886136A (zh) 2006-12-27
CA2540102C (en) 2012-07-24
IL174536A0 (en) 2008-04-13
US20070275989A1 (en) 2007-11-29
KR101129767B1 (ko) 2012-03-26
JP2007506720A (ja) 2007-03-22
MXPA06003353A (es) 2006-06-08
RU2358737C2 (ru) 2009-06-20
GB0322552D0 (en) 2003-10-29
RU2006113366A (ru) 2007-11-10
IS8421A (is) 2006-04-21
IS2729B (is) 2011-04-15
AU2004275567A1 (en) 2005-04-07
US7932263B2 (en) 2011-04-26
CA2540102A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
MXPA05010706A (es) Uso de un inhibidor del transporte de acido biliar ileal (ibat) para el tratamiento o profilaxis del estrenimiento.
BR0317715A (pt) Composições e processos de uso de collajolie
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
TR200103216T2 (tr) Pirimidinon bileşimleri
DE602004002633D1 (de) Chromfreies Mittel zur Behandlung von Metalloberflächen
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
WO2006081276A8 (en) 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
WO2005044194A3 (en) TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
BRPI0509420A (pt) método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DE60129330D1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
EE04581B1 (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
AU2003211009A1 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
PL1608685T3 (pl) Antagoniści VEGF do leczenia cukrzycy
BR0301681B1 (pt) Trava de segurança para portas domésticas e similares
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE491457T1 (de) Kombinationstherapie gegen tumoren mit substituierten acryloyl-distamycin-derivaten, taxanen und/oder antimetaboliten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]